Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A Yoneyama
I.v. BU/fludarabine Plus Melphalan or TBI in Unrelated Cord Blood Transplantation for High-Risk Hematological Diseases
Bone Marrow Transplantation
Transplantation
Hematology
Related publications
Excellent Survival Chances After Pharmacokinetic-Targeted Busulfan Plus Fludarabine and ATG for Children With Hurler Syndrome Undergoing Unrelated Cord Blood Transplantation
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Busulfan, Fludarabine, and Alemtuzumab Conditioning and Unrelated Cord Blood Transplantation in Children With Sickle Cell Disease
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Risk Factors and Options to Improve Engraftment in Unrelated Cord Blood Transplantation
Stem Cells International
Cell Biology
Molecular Biology
Melphalan 140mg/M2 Combined With TBI2(4)Gy and Fludarabine 125mg/M2 as Conditioning for Elderly Patients With Hematological Malignancies in Unrelated Bone Marrow Transplantation Is Comparable in Safety and Effectiveness With TBI/Cy for Younger Patients
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Unrelated Cord Blood Transplantation in CML: Japan Cord Blood Bank Network Analysis
Bone Marrow Transplantation
Transplantation
Hematology
Role of HLA Compatibility in Unrelated Cord Blood Transplantation
Major Histocompatibility Complex
Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide
Haematologica
Hematology
Optimization of Unrelated Donor Cord Blood Transplantation for Thalassemia: Implications for Other Non‐Malignant Indications Such as HIV Infection or Autoimmune Diseases
Treatment of Fanconi Anemia Patients Using Fludarabine and Low-Dose TBI, Followed by Unrelated Donor Hematopoietic Cell Transplantation
Bone Marrow Transplantation
Transplantation
Hematology
